Biologics. Amgen makes several therapeutic drugs that target serious disease. Many are derived from engineered monoclonal antibodies. Some target immune receptors.
Apitope is a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases.
A biopharmaceutical company that focuses on Cardiovascular and Metabolic diseases, Oncology, and Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal diseases, ...
Benaroya Research Institute's mission is to find the causes and cures of autoimmune diseases, including diabetes, lupus, cancer, MS, heart disease and others.
Compugen, via its wholly-owned subsidiary Compugen USA, Inc., is developing therapeutic antibodies against selected target proteins both for cancer immunotherapy and antibody-drug conjugate ...
DxTerity is a patient-centric genomics company bringing the power of real-world genomics with from-home RNA monitoring to improving the management of immune-mediated disease.
InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. Through a combination of internal ...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Their pipeline ...
Landos' unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases.
A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious ...
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of ...
The goal of Topas (Tolerizing Particles) is to develop novel therapeutics to treat a variety of immune-mediated and autoimmune diseases. The technology platform induces antigen-specific immune ...
